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ABSTRACT 
Objective; to assess the internal consistency, construct validity and sensitivity to 
change of a pelvic organ prolapse symptom score (POP-SS). 
Design; analysis of data from three prolapse studies, including symptomatic and 
asymptomatic women, who completed the POP-SS.  
Setting; 1) a community setting in New Zealand; 2) two gynaecology outpatient 
departments in Scotland; 3) a gynaecological surgery department in Scotland. 
Population or sample; 1) participants from a survey of post-natal women at 12 year 
follow up, invited to complete a prolapse questionnaire and have prolapse 
assessment; 2) new gynaecology outpatients presenting with prolapse symptoms, 
randomised to pelvic floor muscle training (PFMT) or control; 3) women having 
anterior and/or posterior prolapse surgery, randomised to mesh insert or no mesh. 
Methods; data were analysed to assess internal consistency, construct validity and 
sensitivity to change of the POP-SS. 
Main outcome measures; Cronbach’s alpha, significance of differences in POP-SS 
scores between studies, significance of difference in POP-SS scores pre- to post-
intervention. 
Results; For internal consistency, Cronbach’s alpha ranged from 0.723 to 0.828.  
Women having surgery had higher POP-SS scores than those having conservative 
management (mean difference 5.0, 95% confidence interval 3.1 to 6.9), who in turn 
had higher scores than the asymptomatic women (mean difference 5.9, 95% CI 4.4 
to 7.4).  Significant differences in POP-SS score were detected after surgery and 
PFMT.  The improvement due to surgery was significantly greater than that 
associated with PFMT (z = -3.006, p= 0.003). 
Conclusions; The POP-SS has good internal consistency and construct validity, and 
is sensitive to change.  (250 words) 
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INTRODUCTION 
Pelvic organ prolapse (POP), a common female condition, is symptomatic descent, 
from the normal anatomical position, of the vaginal walls, apex or vault 1.  Women 
with prolapse present with a variety of symptoms (vaginal, urinary, bowel, back, 
abdominal and sexual symptoms).  Some of these symptoms are specifically 
associated with the descending pelvic organs protruding into the vaginal canal, for 
example, feeling of a bulge or something coming down.  Others, such as urinary and 
bowel problems, can co-exist and may be related to or independent of the prolapse.  
It is important in research and clinical practice that we quantify such symptoms using 
standardised instruments with known psychometric properties. 
 
Many instruments exist for measuring urinary symptoms and associated quality of 
life, including 17 questionnaires which the International Consultation on Incontinence 
(ICI) classed as Grade A (i.e. having established reliability, validity and 
responsiveness demonstrated in one or more datasets) 1.  Far fewer are available for 
the specific symptoms of prolapse.  The ICI in 2005 1 concluded that questionnaires 
in this area were “poorly developed to date and required encouragement”; two 
questionnaires of Grade B (validity and reliability established with rigour, or validity, 
reliability and responsiveness indicated) were identified (Pelvic Floor Disorder 
Inventory (PFDI) 2 and Pelvic Floor Impact Questionnaire (PFIQ) 2), and an additional 
five which were in early development (Grade C) (e.g. P-QoL, ICIQ Vaginal Symptoms 
Questionnaire).   
 
Since then work has been published on the above prolapse measures (short-form 
versions of the PFDI and PFIQ 3; the P-QoL 4; ICIQ Vaginal Symptoms Questionnaire 
5).  The most prominent of these measures 2,4 are fairly lengthy, cover a range of 
symptoms and include a number of subscales, for example relating to urinary and 
bowel symptoms.  It could be argued that these commonly co-existing symptoms are 
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better measured using validated, condition-specific instruments such as those 
developed by the International Consultation on Incontinence Questionnaire (ICIQ) 
group 6, and that there remains a need for a brief symptom index which encapsulates 
the presence and extent of key prolapse symptoms.  We report here on a scale 
which fulfils this need. 
 
At the start of a programme of work on prolapse in 2000, when we sought a brief 
validated prolapse symptom scale, no suitable scale was available.  We thus 
developed a simple set of key questions covering the symptoms caused or 
exacerbated specifically by prolapse which could serve as the primary outcome 
measure for subsequent randomised controlled trials of various interventions for 
POP.  The key questions formed the basis for a POP symptom scale (POP-SS). 
 
Our intention was to supplement the POP-SS with a number of existing validated 
scales aimed specifically at urinary (ICIQ-UI SF 7), bowel (ICIQ-BS 6) and sexual 
symptoms (PISQ-12 8), so that these functions could be assessed independently.   
 
We administered the POP-SS to women in a number of research studies in order to 
generate data on its acceptability and performance.  This article presents the findings 
regarding psychometric properties of the POP-SS, including internal consistency, 
construct validity and sensitivity to change. 
 
METHODS 
 
The Pelvic Organ Prolapse Symptom Score 
The POP-SS consists of seven items, each with a 5-point Likert response set 
(0=never, 1=occasionally, 2=sometimes, 3=most of the time, 4=all of the time) (Table 
1).  The question format and response set were modelled on those used by the ICIQ 
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group to standardise outcome measures in pelvic floor dysfunction research and 
clinical practice 6.  The items were developed from reviewing the literature in the 
course of undertaking a number of prolapse-related Cochrane systematic 
reviews9,10,11, and from discussion with gynaecologists, physiotherapists and women 
with prolapse.  Some of the items are similar to those in other instruments since they 
target universally acknowledged symptoms associated with prolapse (e.g. a feeling of 
something coming down in the vagina).  A total score (range 0 to 28) is calculated by 
summing the seven individual symptom responses to derive the POP-SS score.  In 
addition, women indicate which one of the seven symptoms causes them most 
bother (Table 1). 
 
At an early stage the POP-SS was assessed in qualitative interviews with 10 women 
(mean age 49 years) during which they completed the seven questions as part of a 
larger questionnaire.  Women, who had either stage I (n=5) or II (n=5) prolapse, were 
purposively selected to represent the range of prolapse types (4 rectocele, 3 
cystocele, 2 rectocele+cystocele, 1 uterine prolapse).  The “think aloud” method 12 
was used to encourage women to make explicit their understanding of the questions 
and rationale for responses chosen.  Women were also asked to comment on the 
comprehensiveness and acceptability of the questionnaire.  This approach provided 
evidence of content validity and acceptability, since women could understand the 
questions, and found them acceptable and relevant to the symptoms that troubled 
them in relation to their prolapse 13. 
 
The POP-SS has to date been used in three studies 14.15,16, undertaken by the same 
research group, described below. 
 
 
Datasets 
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In New Zealand in 2005, 435 women were followed up 12 years after giving birth, at 
which time they had responded to a survey investigating postnatal urinary and faecal 
incontinence 17.  All women completed the POP–SS, and a sub-group of 166 women 
agreed to have objective prolapse assessment using the Pelvic Organ Prolapse – 
Quantification system (POP-Q) 18.  Women were not known to be symptomatic of 
prolapse: they were selected entirely on the basis of their involvement in the earlier 
survey. 
Study 1: PROlapse and incontinence: LONG-term research (ProLong) 14 
 
In 2003/04, in a feasibility study at two Scottish centres, focussing on stage I or II 
prolapse, 47 women were randomised to either a pelvic floor muscle training (PFMT) 
intervention group or a control group receiving only a prolapse-related lifestyle advice 
leaflet.  Objective quantification of prolapse type and severity was carried out at 
baseline and 6 months in both groups using the POP-Q 18, and women completed a 
postal questionnaire including the POP-SS at baseline, 20 and 26 weeks. 
Study 2: Pelvic Organ Prolapse PhysiotherapY (POPPY) feasibility study 15 
 
In 2005 at one Scottish gynaecology centre, 66 women completed the POP-SS 
before and 6 months after having prolapse surgery (anterior and/or posterior repair).  
No POP-Q data were collected. 
Study 3: Insertion of Mesh or sutures for PRolapsE Surgery Success (IMPRESS) 16 
 
Analysis of the data resulting from these studies contributed information regarding 
internal consistency, construct validity and sensitivity to change of the POP-SS. 
 
Psychometric properties 
It is desirable for questions within a scale which are measuring the same concept, in 
this case extent of prolapse symptoms, to have high correlation; a property known as 
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“internal consistency”.  Internal consistency of the POP-SS was assessed using data 
from Studies 1, 2 and 3.   
 
A valid scale is one which measures what it intends to, and this is best assessed by 
comparison with a “gold standard” measure of the same quantity (criterion validity) 19.  
When no gold standard measure exists, as is the case for prolapse symptoms, it is 
appropriate to assess construct validity instead.  Hypotheses or constructs can be 
established regarding the responses to the scale, and if the hypotheses are 
supported by the data this provides evidence of construct validity.  A form of 
construct validity known as trait validity was investigated via the hypothesis that 
scores at baseline (i.e. prior to any treatment) would be lowest in an asymptomatic 
group of women (Study 1), followed by a conservative management group (Study 2), 
and highest in a surgical intervention group (Study 3). 
 
Ability to detect change in prolapse symptoms due to an intervention is an important 
scale property.  Sensitivity to change of the POP-SS was assessed by testing for a 
significant pre- to post-intervention improvement in scores using data from Study 2 
(PFMT intervention) and Study 3 (surgical intervention).  The improvement in scores 
was expected to be greater in Study 3. 
 
Statistical analysis 
The three data sets described above were analysed separately and combined as 
appropriate to examine the properties of the POP-SS.  The POP-SS scores were 
found to be non-normally distributed in several of the samples, particularly post-
intervention when symptoms are likely to have resolved, thus primarily non-
parametric methods were used.   
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Cronbach’s alpha 20 was used to assess internal consistency of the seven item POP-
SS using data from Studies 1, 2 and 3.  Good internal consistency was assumed if 
Cronbach’s alpha was between 0.7 and 0.9 21.  It is undesirable for alpha to be too 
high as this suggests redundancy in the items of the scale. 
 
In assessing trait validity, initially mean and median scores for the three study groups 
were tabulated.  Non-parametric one-way analysis of variance (Kruskal-Wallis) was 
used to test for a significant difference between groups.  Parametric analysis of 
variance, with post-hoc t-tests of differences between group means with Bonferroni 
correction, was also performed. 
 
In terms of sensitivity to change, the Wilcoxon paired test was used to test for 
statistically significant differences between pre- and post-intervention POP-SS scores 
within studies.  Differences between studies in pre- to post-intervention change in 
score were tested using the Mann-Whitney U test. 
 
Analysis was undertaken using SPSS software and a 5% level of significance was 
used throughout.   
 
RESULTS 
 
Sample characteristics 
The women in Study 3 (surgery group) were oldest and those in Study 1 
(asymptomatic) were youngest, reflecting the differing study populations (Table 2). 
 
Internal consistency 
The correlation amongst questions within the POP-SS was assessed in individual 
study datasets.  Cronbach’s alpha values (Table 3) indicate that the POP-SS seven 
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items have good internal consistency, i.e. alpha > 0.7.  The POPPY study (Study 2), 
which had the smallest sample size, had slightly lower Cronbach’s alpha for both 20 
and 26 week follow up time-points. 
 
Construct validity 
The median POP-SS score at baseline was highest in the surgery study (Study 3), 
followed by the conservative intervention study (Study 2), and lowest in the study of 
asymptomatic women (Study 1) (Table 2).  A significant difference between groups 
(Kruskal-Wallis Χ2 = 176.730, df = 2, p<0.001) was detected.  The ProLong mean 
score was significantly lower than that at baseline from POPPY (mean difference -
5.9, 95% CI [-7.4, -4.4]) and IMPRESS (mean difference -10.9, 95% CI [-12.2, -9.6]), 
and the baseline POPPY mean score was significantly lower than that for IMPRESS 
(mean difference -5.0, 95% CI [-6.9, -3.1]).  That is, the POP-SS scores differed 
between studies in a predictable way. 
 
Table 1 highlights where differences in POP-SS scores between studies arose from.  
In the asymptomatic group of women (Study 1) a low percentage responded 
positively to having each of the seven symptoms.  A feeling of incomplete bladder 
(38%) and bowel (46%) emptying were the symptoms most commonly reported, and 
the latter was the symptom which women said caused most bother.  In contrast only 
16% reported a feeling of something coming down.  Percentages were consistently 
higher (in excess of 50% for each symptom) in the conservative treatment group 
(Study 2), with the most commonly reported symptom being a feeling of something 
coming down (79%) (Table 1).  In the surgical group (Study 3) the percentages were 
highest of all studies, across all symptom questions.  Most women in this study 
reported a feeling of something coming down (89%): this was both the most 
prevalent symptom (but not reported by everyone) and the one which most women 
identified as causing most bother. 
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Sensitivity to change 
In both the POPPY and IMPRESS studies a significant decrease in score after the 
interventions was detected (Table 4).  The average decrease in score was shown to 
be significantly greater in the IMPRESS women than in the POPPY women (z = -
3.006, p= 0.003), i.e. there was greater improvement in the surgery group than the 
PFMT group.  Thus the POP-SS was able to detect the changes brought about by 
both types of intervention, and a difference in the magnitude of the change was 
distinguishable between studies. 
 
DISCUSSION 
Summary of aims 
Our objective was to investigate the psychometric properties of a brief prolapse 
symptom scale (POP-SS) which might be used as an outcome measure in future 
trials of various prolapse interventions, and in clinical practice.  No suitable validated 
scale of this nature was available at the onset of our programme of work.  There are 
now a number of published prolapse instruments which are reported to be valid and 
reliable, however their length and complexity may make them impractical for some 
purposes.  To our knowledge a reliable, valid and sensitive scale such as the POP-
SS is still lacking in the literature. 
 
Internal consistency 
Good internal consistency was confirmed across the three studies, and the POP-SS 
compared favourably with other instruments in this respect.  Digesu et al 4 found 
Cronbach’s alpha to be in excess of 0.80 in their assessment of the P-QoL, and 
Barber et al 2 reported Cronbach’s alpha of 0.82 for the Pelvic Organ Prolapse 
Distress Inventory and 0.97 for the Pelvic Organ Prolapse Impact Questionnaire, 
which are the relevant subcales of the PFDI and PFIQ.  It is reassuring that all POP-
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SS items appear to be measuring the same trait, that is, there is homogeneity of the 
items within the scale.  The value of Cronbach’s alpha did not exceed 0.9 which 
would have suggested that the questions were too highly correlated and that some 
items were redundant.  The findings suggest that a simple summation of scores over 
the seven symptom questions makes a reasonable index 19. 
 
It is interesting that the internal consistency of the POP-SS is good (Cronbach’s 
alpha 0.823) in a sample of women selected without knowledge of their status with 
regards to prolapse (ProLong).  This is encouraging if the POP-SS were to be used 
in trials of interventions to prevent prolapse. 
 
Validity 
The three study populations were representative of women with differing profiles of  
prolapse.  Study 1 comprised a group of women who had participated in a post-natal 
survey 12 years previously, and for whom prolapse status was therefore unknown.  
Study 2 included women opting for conservative treatment, predominantly with stage 
I or II prolapse.  Finally, Study 3 included women with prolapse of stage II or greater, 
having prolapse repair surgery.  These groups of women would be expected to have 
different symptoms leading to their differing treatment choices, or in the case of 
Study 1, to no treatment for prolapse being sought.  The ability of the POP-SS to 
differentiate between these groups, as indicated by the significant difference in 
scores, supports the trait validity of the scale.  The predicted ordering in average 
group scores was observed in the data, providing additional evidence of validity.  In a 
similar analysis the P-QoL domain scores were also found to differ significantly 
between symptomatic and asymptomatic women 4.  Other studies have investigated 
validity in terms of the relationship between symptom scores and prolapse severity, 
however, to date, it is not clear whether increasing symptoms are correlated with 
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increasing prolapse severity 22.  Analysis of the relationship between the POP-SS 
and the POP-Q is underway, and will contribute information to this debate. 
 
 
Sensitivity to change 
POP-SS could detect change due to both conservative and surgical interventions, 
and as expected the improvement in symptoms was greater in women who had 
surgery.  This is an important property for a scale which is to be used in trials 
establishing the effectiveness of interventions for treatment of prolapse.  The 
sensitivity to change of the P-QoL and PFDI/PFIQ has not been reported.  The short 
forms of the PFDI and PFIQ were however found to have moderate to excellent 
responsiveness 3 to 6 months after surgery 3. 
 
Implications for further research/use of POP-SS 
Our aim was to develop a scale which was brief and contained only the key 
symptoms important in obtaining a view of how prolapse is affecting a woman.  It 
could be argued that the three questions within the POP-SS relating to bladder and 
bowel are not symptoms experienced exclusively by women with prolapse.  
Generally we avoided in our scale such questions, however these symptoms, more 
than others, are linked frequently with prolapse and were regarded to be worth 
including.  The feeling of incomplete emptying of the bladder and bowel were the 
symptoms most commonly reported in the ProLong study (Study 1) in which women 
did not necessarily have prolapse.  This perhaps reflects the fact that these 
symptoms are experienced generally by women other than those with prolapse.  The 
prevalence of these symptoms was, however, far higher in the studies of women with 
confirmed prolapse. 
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The POP-SS was developed from a wide perspective, drawing on published 
research, clinical expertise and qualitative data from women with prolapse.  It would 
be desirable to undertake further qualitative work investigating how women with 
different profiles respond to POP-SS items, and how well changes in scores reflect 
important modifications in their symptoms.   Data are being gathered currently on the 
test-retest reliability of the POP-SS, and on its relationship with the observed POP-Q 
measure.  Examination of the psychometric properties of the POP-SS in other 
treatment groups, for example women being fitted with a vaginal pessary, is also 
warranted. 
 
In prolapse research the choice of an appropriate measure is still the subject of 
debate.  There is a need to review and produce recommendations on the currently 
available prolapse questionnaires.  
 
Conclusion 
It has been shown that the POP-SS is a measure with good internal consistency; it is 
valid as a measure of prolapse symptoms as scores differed predictably between 
groups of women known to differ in their prolapse symptoms; finally, it is sensitive to 
the change brought about by treatment for prolapse, specifically surgical repair and 
PFMT. 
 
The POP-SS is a brief questionnaire which is acceptable to women and lends itself to 
both the research and the clinical environment. 
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Table 1  Pelvic Organ Prolapse Symptom Scale: percent of women responding 
positively to symptom questions in each study 
 
How often during the last four weeks have you had the following symptoms (0=never, 
1=occasionally, 2=sometimes, 3=most of the time, 4=all of the time): 
  Study 1 
ProLong 
N = 435 
Study 2 
POPPY 
N = 47 
Study 3 
IMPRESS 
N = 66 
A1 a feeling of something coming down 
from or in your vagina? 
16.2%     78.7% 
 
89.2% 
A2 an uncomfortable feeling or pain in your 
vagina which is worse when standing? 
13.0% 67.4% 70.8% 
A3 a heaviness or dragging feeling in your 
lower abdomen / tummy?    
27.0% 63.8% 81.5% 
A4 a heaviness or dragging feeling in your 
lower back? 
23.7% 59.6% 66.2% 
A5 a need to strain (push) to empty your 
bladder?  
24.1% 56.5% 72.3% 
A6 a feeling that your bladder has not 
emptied completely? 
38.1% 63.8% 87.7% 
A7 a feeling that your bowel has not 
emptied completely? 
46.4% 63.8% 76.9% 
*A8 which of the symptoms above 
(questions A1 to A7) causes you most 
bother? 
A7 
39.3% 
N/A A1 
40.0% 
 
* The symptom most often identified as causing most bother is shown, with the 
percentage of respondents which chose this symptom.  This question was used only 
in Study 1 and Study 3.   
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Table 2  Characteristics of women from included studies 
Variable Study 1 Study 2 Study 3 
Maximum sample size 435 
(166 with 
POP-Q) 
47 66 
Median age in years 
(range) 
40 
(28, 57) 
57 
(31, 72) 
61 
(43, 84) 
POP-Q at baseline n (%): 
Stage 0 
I 
II 
III 
 
3 (2) 
59 (35) 
101 (61) 
3 (2) 
 
#1 (2) 
13 (29) 
30 (67) 
#1 (2) 
 
all women were 
stage II, III  
or IV 
 
Leading edge POP 
type n (%):            anterior 
posterior 
anterior=posterior 
superior 
 
86 (52) 
32 (19) 
43 (26) 
3 (1) 
 
17 (70) 
4 (16) 
2 (8) 
1 (4) 
 
30 (48) 
13 (20) 
*19 (30) 
 
Median POP-SS (range) 
Baseline 
20 wks/6 mnths post-intv 
26 weeks post-intv 
 
1 (0, 16) 
n/a 
n/a 
 
8 (0, 21) 
7.5 (2, 21) 
6 (1, 21) 
 
13 (3, 28) 
3 (0, 22) 
n/a 
*  women who had both anterior and posterior repair were assumed to have equal 
leading edges 
# 1 woman presenting with prolapse symptoms but found to be stage 0 on 
examination was included.  1 woman with stage 3 prolapse was erroneously 
included. 
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Table 3  Internal consistency of the POP-SS 
Study Cronbach’s alpha N 
Study 1 0.823 421 
Study 2: 
Baseline 
20 weeks 
26 weeks 
 
0.798 
0.737 
0.723 
 
45 
38 
39 
Study 3: 
Pre-op 
6-mnths post-op 
 
0.819 
0.828 
 
65 
62 
 
 21 
Table 4  Sensitivity to change of the POP-SS: paired tests 
Study mean pre-
intervention 
mean post-
intervention 
mean difference 
(pre – post) 
n Wilcoxon p 
value 
Study 2 9.05 6.11 3.47 *17 -2.308 0.021 
Study 3 13.52 4.34 9.20 61 -6.069 <0.001 
* only data from intervention women are included: control women received only a 
lifestyle leaflet, and no significant change in POP-SS score was detected 
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